Basilea Pharmaceutica Ltd. Logo

Oncology 2015



  • AACR-NCI-EORTC, 2015, A183 / The novel tubulin-binding 'tumor checkpoint controller' BAL101553 exerts EB1 expression dependent antitumor effects on glioblastoma stem-like cells in vitro and in vivo. Berges R, Tchoghandjian A, Honore S, Figarella-Branger D, Bachmann F, Lane H, Braguer D.
  • ASCO, 2015, TPS2611 / A randomized Phase 2a study to assess pharmacodynamics, antitumor activity and safety of intravenous BAL101553, a novel microtubule inhibitor, at two dose levels in adult patients with selected advanced solid tumors. Kristeleit RS, Smith AD, Md. Haris N, Zubairi IH, King JW, de Miguel Luken M-J, D'Archangelo M, MacDonald J, Brown NF, Calvert AH, Hannah AL, Anderson S, Bachmann F, Maurer M, Schmitt-Hoffmann A, Lane H, Engelhardt MF, Evans JTR, Plummer R, Molife LR.
  • AACR, 2015, 3789 / BAL101553 (prodrug of BAL27862): the 'Spindle Assembly Checkpoint' is required for anti-cancer activity. Burger K, Bachmann F, Lane H.